These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17069529)

  • 1. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.
    Roigas J; Johannsen M; Ringsdorf M; Massenkeil G
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1449-58. PubMed ID: 17069529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer.
    Arya M; Chao D; Patel HR
    Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
    Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
    Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
    Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
    Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
    Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
    Takahashi Y; Childs RW
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hemopoietic stem cell transplantation in solid tumors.
    Carnevale-Schianca F; Ricchiardi A; Capaldi A; Bucci AR; Grignani G; Rota-Scalabrini D; Fizzotti M; Aliberti S; Aglietta M
    Transplant Proc; 2005; 37(6):2664-6. PubMed ID: 16182778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-myeloablative allogeneic stem cell transplantation: a promising new therapy in the management of metastatic renal cell cancer.
    Arya M; Gommersall LM; Shergill IS; Patel HR; Chao D
    BJU Int; 2005 Sep; 96(4):474-5. PubMed ID: 16104893
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma.
    Yun T; Lee KW; Song EG; Na II; Shin HC; Yoon SS; Park SY; Kim BK; Lee JH; Choi SJ; Lee JH; Lee KH
    Clin Transplant; 2007; 21(3):337-43. PubMed ID: 17488382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
    Nelson RP; Logan TF; Abonour R
    Bone Marrow Transplant; 2002 Dec; 30(12):805-12. PubMed ID: 12476272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect.
    Takami A; Takamatsu H; Yamazaki H; Ishiyama K; Okumura H; Ohata K; Konaka H; Asakura H; Namiki M; Nakao S
    Bone Marrow Transplant; 2006 Dec; 38(11):729-32. PubMed ID: 17028623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
    Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
    Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
    Childs RW
    Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term graft-versus-tumor effect following reduced intensity hematopoietic stem cell transplantation in a child with metastatic renal cell carcinoma.
    Baek HJ; Han DK; Hwang TJ; Bae SH; Choi YD; Kook H
    Pediatr Blood Cancer; 2012 Sep; 59(3):583-5. PubMed ID: 22231905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.
    Kami M; Makimoto A; Heike Y; Takaue Y
    Jpn J Clin Oncol; 2004 Dec; 34(12):707-16. PubMed ID: 15640500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation.
    Artz AS; Kocherginsky M; Van Besien K
    Br J Haematol; 2006 Mar; 132(6):747-54. PubMed ID: 16487176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.